@ukpdam she actually says 75% but IMO, she should have read 75 of 90 patients so 83% (see captions)
see 5.15 mark - thanks to @randomvirus and @dplane
May be leaked information?
83% would represent IMO, overwhelming efficacy I would have thought !
I’m looking forward to the 90 patient readout by the independent Data Safety Monitoring Board (DSMB) who will complete the first interim analysis of the Phase 3 trial of Remestemcel-L in ventilator dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) in early September!
Cell Therapy News/Articles, page-5687
-
- There are more pages in this discussion • 12,356 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |